HUDSON: An Open-Label, Multi-Drug, Biomarker-Directed, Phase II Platform Study in Patients with NSCLC, who Progressed on Anti-PD(L)1 Therapy

被引：18

作者：

Besse, B. ^{[1
]}

Awad, M. ^{[2
]}

Forde, P. ^{[3
]}

Thomas, M. ^{[4
]}

Park, K. ^{[5
]}

Goss, G. ^{[6
]}

Rizvi, N. ^{[7
]}

Huemer, F. ^{[8
]}

Hochmair, M. ^{[9
]}

Bennouna, J. ^{[10
,11
]}

Cosaert, J. ^{[11
]}

Szucs, Z. ^{[11
]}

Mortimer, P. ^{[11
]}

Hobson, R. ^{[11
]}

Sachsenmeier, K. ^{[12
]}

Dean, E. ^{[11
]}

Ambrose, H. ^{[11
]}

Hayward, C. ^{[11
]}

Dressman, M. ^{[11
]}

Barry, S. ^{[11
]}

Heymach, J. ^{[13
]}

机构：

[1] Clcc Inst Gustave Roussy, Villejuif, France

[2] Dana Farber Canc Inst, Boston, MA 02115 USA

[3] Johns Hopkins Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD USA

[4] Univ Klinikum Heidelberg, Thoraxklin, Heidelberg, Germany

[5] Sungkyunkwan Univ, Samsung Med Ctr, Sch Med, Seoul, South Korea

[6] Ottawa Hosp Res Inst, Ottawa, ON, Canada

[7] Columbia Univ, Med Ctr, New York, NY USA

[8] Otto Wagner Hosp, Dept Resp Med 2, Vienna, Austria

[9] Karl Landsteiner Inst Lung Res & Pulm Oncol, Klin Floridsdorf, Dept Resp & Crit Care Med, Vienna, Austria

[10] Univ Nantes, Nantes, France

[11] Astrazeneca, Res & Early Dev Oncol, Cambridge, England

[12] Astrazeneca, Oncol Translat Med, Boston, MA USA

[13] MD Anderson Canc Ctr, Houston, TX USA

来源：

JOURNAL OF THORACIC ONCOLOGY | 2021年 / 16卷 / 03期

关键词：

HUDSON; Durvalumab; platform study;

D O I：

10.1016/j.jtho.2021.01.299

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

OA07.08

引用

页码：S118 / S119

页数：2